Seven-Site Pilot Spanning Pharma, Facility Management, Energy and Utilities to Validate AI Nose as Next-Gen Industrial AI at Scale
Robots Gain a New Sense: AI Nose Leverages Smell Language Model for Smart Scent Analytics
Read MoreFrom sweetheart to showstopper: A bold and expressive collection of exclusive designs at accessible prices and sizes, plus extra savings for Diamond Loyalty Members, making David's Bridal the ultimate Homecoming Headquarters
Read More
Multiple battery system products launched for new robotic vehicle platforms for three distinct OEM customers with applications ranging from material handling to surveillance systems
Part of a major product development effort to target the rapidly growing robotics segment, leveraging the Company's technology advantages around battery safety and longevity
Read More
All the news about the DEA administrator and Rescheduling marijuana means absolutely nothing if the quota system remains untouched.
Much attention has been given to breaking Ole Miss's monopoly and who becomes the next DEA Administrator. But the real news isn't about who's appointed-it's what the DEA does with the quota system.
Read More
A non-medical overview of how Sprout Health NAD⁺ Injections supports energy, cellular function, and wellness in a remote telehealth setting.
Read More
UPDATE - Contact information has been updated on this release as of September 9, 2025
A remote-first, doctor-reviewed telehealth program offering access to personalized care plans and GLP-1 evaluations using semaglutide or tirzepatide.
At-home medical service offers streamlined access to GLP-1 prescriptions like Ozempic®, Semaglutide, and Tirzepatide with no insurance requirements or in-person visits.
Read More
-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition
-- CID-103 is a potential best in class, anti-CD38 monoclonal antibody, currently dosing in a multi-center Phase 1/2 study in adults with chronic immune thrombocytopenia (ITP); IND submitted to support future clinical trials in adults with renal allograft antibody-mediated rejection (AMR)
Read More